Strategy for selection of clinical doses for SBT101, a gene therapy for the treatment of adrenomyeloneuropathy (AMN)

Time: 2:30 pm
day: Day One: Track B PM


  • Selection of AAV vector and delivery for AMN
  • How target engagement and efficacy studies supported starting dose
  • Safety studies further supported dose selection